

TANDEM DIABETES CARE INC
Form 8-K
December 19, 2017

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 15, 2017

Tandem Diabetes Care, Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction

of incorporation)

001-36189
(Commission

File Number)

20-4327508
(I.R.S. Employer
Identification No.)

11075 Roselle Street,

San Diego, CA

(Address of principal executive offices)

92121

(Zip Code)

Registrant's telephone number, including area code: (858) 366-6900

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

As previously reported by Tandem Diabetes Care, Inc. (the Company) in a Current Report on Form 8-K filed on December 7, 2017, Leigh Vosseller, who is currently serving as the Company's Senior Vice President of Finance, will be appointed as the Company's Senior Vice President and Chief Financial Officer effective January 1, 2018.

On December 15, 2017, the Compensation Committee of the Board of Directors of the Company (the Committee) approved an increase in the base salary to be received by Ms. Vosseller for fiscal year 2018 to \$345,000, effective on January 1, 2018. In addition, the Committee approved (i) a target cash bonus percentage in an amount equal to 40% of Ms. Vosseller's base salary for fiscal year 2017 (to be applied to the full year), and (ii) a target cash bonus percentage in an amount equal to 50% of Ms. Vosseller's base salary for fiscal year 2018, with the actual cash bonus amounts for each of fiscal years 2017 and 2018, if any, to be determined at the discretion of the Committee.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Tandem Diabetes Care, Inc.

By: */s/ David B. Berger*

David B. Berger

Executive Vice President, General
Counsel and Secretary

Date: December 19, 2017